Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.67 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19752684 | 0.78 | POLB (1.00) | CYP3A4CYP2C9CYP2C19ALOX12POLB | |
| SCHEMBL19752686 | 0.78 | POLB (1.00) | CYP3A4CYP2C9CYP2C19ALOX12POLB | |
| SCHEMBL10113389 | 0.78 | LMNA (0.80) | CYP3A4CYP2C9CYP2C19ALOX12POLB | |
| SCHEMBL19590933 | 0.78 | CYP2C9 (0.59) | CYP3A4CYP2C9CYP2C19ALOX12POLB | |
| SCHEMBL10113724 | 0.77 | ALDH1A1 (0.61) | TSHRALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL10113726 | 0.76 | ALDH1A1 (0.70) | TSHRALDH1A1SMN1; SMN2HTTLMNA | |
| SCHEMBL9865516 | 0.75 | PYGL (0.48) | CYP3A4CYP2C9CYP2C19ALOX12POLB | |
| SCHEMBL14164088 | 0.75 | CA1 (0.78) | CYP3A4CYP2C9CYP2C19ALOX12POLB | |
| SCHEMBL31706859 | 0.75 | CA1 (0.78) | CYP3A4CYP2C9CYP2C19ALOX12POLB | |
| SCHEMBL10113258 | 0.74 | TSHR (0.75) | CYP3A4CYP2C9CYP2C19ALOX12POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389529-B2 | Methods and compositions for treating asthma | HYDRA BIOSCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178542-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | CYP3A4 3970/4885CYP2C9 2647/4885CYP2C19 2785/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | CYP3A4 4673/4885CYP2C9 4335/4885CYP2C19 4471/4885 |
| US-20140221401-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | CYP3A4 3970/4885CYP2C9 2647/4885CYP2C19 2785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.